FDA convenes advisory panel to review BrainStorm's ALS therapy NurOwn
BrainStorm Cell Therapeutics' ALS treatment, NurOwn, will be discussed in an FDA advisory committee meeting after receiving a refusal to file letter in November. Ionis and AstraZeneca's rare disease drug, eplontersen, has completed a positive Phase III trial. Codiak BioSciences has filed for Chapter 11 bankruptcy. ArriVent Biopharma has raised $155 million in a Series B round. Endpoints has added three new journalists to their newsroom. Kristen Hege, a cancer researcher, has put her career on hold to hike the Pacific Crest Trail. Another biotech startup has faced a Phase II pileup in Parkinson's disease.